Verbatim response from Claude
This is a fast-moving area, so here's an honest breakdown:
Context First
The FDA declared the semaglutide shortage over in 2024, which triggered a crackdown on compounded versions. The situation for tirzepatide is similar. Rules are still evolving, so availability changes frequently.
Services That Have Continued Offering Compounded GLP-1s (as of early 2025)
- Hims & Hers - fought to continue compounded semaglutide and tirzepatide; has been vocal about legal challenges
- Ro - offered compounded versions but adjusted based on regulatory pressure
- LifeMD/GoTelehealth - continued offering compounded options
- Mochi Health - has offered compounded semaglutide through partner pharmacies
- Henry Meds - has offered compounded options
Important Caveats
- Verify current availability directly - this changes week to week
- Some services pivoted to personalized/combination formulas to maintain a regulatory argument for compounding
- FDA enforcement actions are ongoing and lawsuits are in play
- Quality varies significantly between compounding pharmacies
My Honest Recommendation
Check current status directly with each service, and ask which FDA-registered 503B compounding pharmacy they use - that's a meaningful quality indicator.
Would you like more detail on any specific aspect?